oth coronary artery bypass grafting (CABG) surgery and percutaneous coronary intervention (PCI) have been shown to provide symptomatic relief and to increase longterm survival in patients with coronary artery disease. [1] [2] [3] Hybrid coronary revascularization (HCR) seeks to combine the respective strengths of CABG and PCI in an attempt to offer a technique that is less invasive than conventional surgery without diminishing the efficaciousness of therapy offered.
TAXUS indicates clinical trials evaluating safety and feasibility of paclitaxelcoated stents; ENDEAVOR, clinical trials evaluating safety and feasibility of zotarolimus-eluting phosphorylcholine-encapsulated stents; and SPIRIT, clinical trials evaluating safety and feasibility of everolimus drug-eluting stents. From randomized controlled trials comparing drug-eluting and bare metal stents, the 12-month DES restenosis rate is between 0% and 9.4% with an average of 4.39%, whereas stent thrombosis rarely occurs (range, 0%-1%; average, 0.47%).
CONTROVERSIES IN CARDIOVASCULAR MEDICINE
LIMA-to-LAD graft with those of PCI-to-non-LAD vessels. Because less surgical revascularization is required, the additional possibility of being able to perform the LIMA-to-LAD graft through a minimally invasive incision adds to the appeal of the technique for those who advocate it.
It is important to note, however, that other considerations must be taken into account. A major disadvantage with PCI is that the rates of target vessel revascularization are higher than for CABG. [5] [6] [7] Although CABG has been noted to have higher long-term survival in high-risk patients, the extent of its benefits in low-risk and intermediate-risk patients is not as clearly defined. [1] [2] [3] Issues such as these raise questions about the clinical utility of HCR and what the actual long-term benefits of such a procedure would be. Although multiple observational studies have shown short-term outcomes that are not inferior to CABG alone, 19 -42 no randomized controlled trials with long-term follow-up are currently available. This renders the accurate assessment and proof of the clinical utility of HCR very difficult.
Limitations of Timing
HCR can be performed as a 1-stage or 2-stage procedure. One-stage HCR implies that CABG and PCI are performed contemporaneously in 1 operative environment, separated by minutes. The advocates of this approach favor it because it entails only 1 operational setting, enables completion angiography to assess graft patency, and helps with cost containment because only 1 technical fee involved. Two-stage HCR implies that CABG and PCI are performed in their own respective environments and separated by hours to days. Several limitations apply to both techniques, making it difficult to gauge the clinical utilities of either method.
One-stage procedures can be performed only in a specially designed hybrid operating room that combines the facilities of a cardiac surgery operating room with those of a cardiac catheterization laboratory. The financial commitment, time, resources, and technical requirements for the implementation of a hybrid operating room are rather demanding. Not all institutions, particularly smaller ones, may be aptly equipped with the necessary resources to implement these hybrid operating suites. In addition to personnel, physical and logistical resources must be available. As a result of such stringent requirements, only a limited number of institutions have such facilities, and many institutions that perform HCR do so in 2-stage procedures. In addition, with 1-stage procedures, there may be an increased risk of bleeding and bleeding-related complications from surgery because of the antiplatelet agents required during and after PCI.
In 2-stage procedures, the order in which the procedures are performed imposes different limitations. Those who advocate performing PCI before CABG favor this approach because it does not risk injury to new grafts during PCI and allows lesions not amenable to PCI to be addressed during subsequent CABG. A major limitation, however, is that CABG will have to be performed under the effect of antiplatelet agents such as clopidogrel, increasing the risks of bleedingrelated complications. In addition, the patency of the LIMAto-LAD graft cannot be immediately assessed with this approach, giving it no advantage over conventional surgery in terms of assessing surgical graft patency. Those who advocate performing CABG before PCI favor this approach because it enables PCI under the protection of the LIMA-to-LAD graft, avoids the bleeding risks associated with antiplatelet agents, and allows the assessment of graft patency during subsequent PCI via coronary angiography. A major concern, however, is that if PCI is not successful or has complications, a repeat CABG procedure may be required, which may prove to be substantially higher risk than conventional surgery alone. Additionally, CABG will be performed in the setting of residual coronary artery stenosis in this approach, giving it no major disadvantage in terms of morbidity over conventional surgery.
When describing timing, it is useful to describe the procedural success rates in multivessel stenting versus CABG trials to understand how often a successful multivessel PCI cannot be performed. Most studies have shown the procedural success rates (defined as complete revascularization) of PCI to be lower than those of CABG. In 2010, Morice et al 43 described how 705 randomized patients who had left main disease among the patients with de novo 3-vessel disease and/or left main disease were randomized to PCI with DES or CABG in the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) trial. Complete revascularization for 357 PCI patients versus 348 CABG patients was found to be 64.5% versus 72.5% (Pϭ0.02). Yan et al 44 reported 1309 consecutive patients with multivessel disease involving significant proximal LAD stenosis who underwent PCI with DES (nϭ600) or CABG (nϭ709). Complete revascularization in their series for PCI versus CABG was 68.5% versus 79.7% (PϽ0.001). Banning et al 45 described the results from the SYNTAX study in which 1800 patients (452 with medically treated diabetes mellitus) were randomly assigned to receive PCI with DES or CABG. 
Limitations of Techniques
Although PCI of non-LAD vessels is performed with the standard techniques for stent implantation, multiple techniques exist to perform the LIMA-to-LAD graft. Several of these techniques, however, have a variety of limitations. Hence, the clinical utility of HCR is limited by the technique used and the subset of patients undergoing the particular procedure. This can also prove to be challenging in the sense that the hybrid team not only has to deal with the constraints of the technique involved but also has to have the necessary learning curve to incorporate the technique into a hybrid procedure.
In the minimally invasive direct coronary artery bypass technique, a small anterior or lateral thoracotomy incision through the fourth or fifth intercostal space is used, and a special retractor is used to harvest the LIMA. The LIMA-to-LAD graft is performed via a hand-sewn anastomosis on the beating heart, and a cardiac stabilizer is introduced through the original incision or endoscopically through a separate port incision, which can be used later for chest tube placement. One limitation with this technique is that the patient should be able to tolerate single lung ventilation because it optimizes exposure in this method. Patients who are not able to tolerate single lung ventilation may prove to be more difficult candidates because exposure may be difficult. Patients with a large body habitus may also be more difficult candidates because of exposure. Even though this approach is less invasive, the extensive chest wall retraction required may result in severe postoperative pain.
In the thoracoscopic endoscopic atraumatic coronary artery bypass technique, a port access approach is used to perform a thoracoscopic LIMA takedown. A controlled pneumothorax is required for this technique to generate the optimal anterior mediastinal plane required for the LIMA takedown, after which the surgical anastomosis can be performed on the beating heart. The pneumothorax is induced by insufflating the chest between pressures of 8 and 15 mm Hg. The limitation of this technique is that patients with a small heart and large chest ratio may not be amenable to this approach because they may not tolerate the cardiac displacement and diminished filling pressures.
In the robotically assisted CABG technique, a robotic surgical system performs a robotic LIMA takedown. The LIMA anastomosis is then hand sewn on the beating heart with a small 4-to 5-cm anterior thoracotomy. An endoscopic stabilizer is placed through a different port incision to stabilize the LAD. Insufflations of the chest wall with air are required, and single lung ventilation is used. The limitation with this technique is that patients unable to tolerate single lung ventilation will be difficult candidates. In addition, the outcomes for these procedures are highly dependent on operator experience, skill, and training.
In the totally endoscopic coronary artery bypass technique, an LIMA harvest and anastomosis are performed endoscopically with robotic assistance. They may be performed on a beating heart or on an arrested heart with cardiopulmonary bypass. Once again, the outcomes are highly dependent on operator experience.
Finally, in the conventional sternotomy technique, the LIMA is mobilized and the anastomosis is performed via a sternotomy incision. This technique can be used for HCR when contraindications to the aforementioned minimally invasive approaches exist. It is important to note, however, that this technique offers no distinct advantage over conventional surgery in terms of being minimally invasive.
In addition, multiple other general limitations and contraindications need to be considered. The presence of concomitant valve disease, an intramyocardial LAD, pulmonary conditions that prohibit single lung ventilation, as mentioned previously, and left subclavian artery stenosis are contraindications to minimally invasive direct coronary artery bypass and totally endoscopic coronary artery bypass. 20 Morbid obesity and a history of chest irradiation are relative contraindications to minimally invasive direct coronary artery bypass. 20 Conditions that preclude the institution of peripheral cardiopulmonary bypass are contraindications to totally endoscopic coronary artery bypass with cardiopulmonary bypass. 20 Minimally invasive surgical techniques can also have their limitations. The quality of an LIMA-to-LAD graft performed through a minimally invasive incision may be inferior to that performed through a conventional approach because of the limited exposure.
It is worth noting that the advent of minimally invasive techniques has also sparked interest in what are called hybrid valve-coronary revascularization procedures. The rationale behind these procedures is that using a minimally invasive incision to perform valve surgery combined with PCI can prove to have a distinct advantage in high-risk patients with complex coronary artery disease and valve disease in that it simplifies the operation into 2 lower-risk procedures. The experience with these procedures is currently limited and from isolated single centers. The obvious setbacks are that minimally invasive valve surgery poses new challenges as a result of the requirement that the operation will have to be performed through smaller incisions with endoscopic or longer instruments and that the institution of cardiopulmonary bypass will require specially designated cannulas and techniques. There is also concern regarding the risk of bleeding if the surgery is performed after the PCI and the possibility of stent thrombosis with protamine reversal.
Given these numerous limitations on the surgical techniques used for HCR and the lack of randomized controlled studies with long-term follow-up thereof, it is understandable how the clinical utility of HCR and the subset of patients which would benefit most from HCR are not clearly delineated at the present time. In addition, as stressed earlier, the hybrid team involved not only has to be able to deal with the limitations and learning curve of the surgical techniques involved but also must be able to implement these techniques into a hybrid procedure, which requires an additional and even steeper learning curve.
Current Data, Results, and Limitations
Multiple relatively small retrospective studies have reported their results on HCR since it was first used in 1996. 19 -42 The current data, however, are based on individual institutional experiences. The major limitation is that there are currently no randomized clinical trials on HCR.
Since its initial use in 1996, Ϸ918 patients with coronary artery disease have undergone HCR (Table 3) . 19 -42 Although the data from these studies have shown some encouraging results such as low 30-day mortality (0%-2%) and in-hospital morbidity (0%-21%; average, 4.4%), the rate of percutaneous coronary transluminal angioplasty/stent restenosis at mean follow-up times of 1 to 44 months was between 0% and 30%. 19 -42 This can be attributed in part to the fact that several of the earlier studies used bare metal stents or balloon percutaneous coronary transluminal angioplasty only, with restenosis rates in these studies at follow-up ranging from PTCA indicates percutaneous transluminal coronary angioplasty; PCI, percutaneous coronary intervention; MidCAB, minimally invasive direct coronary artery bypass grafting; DES, drug eluting stent; TECAB, totally endoscopic coronary artery bypass; and BMS, bare metal stent. Most PCI used BMS unless otherwise specified (all PCI before 2003 used BMS).
*DES (99% of patients)/BMS (1% of patients). †DES (63% of patients)/BMS (37% of patients). ‡DES (85% of patients)/BMS (8% of patients)/combined DES and BMS (7% of patients).
2.3% to 23% and averaging 11%. 46 The results of more recent HCR studies using only DES have shown better outcomes. 46 Thirty-day mortality in these studies is 0% to 1.4% and in-hospital morbidity is 0% to 4.2% (average, 1.0%). 46 The rate of stent restenosis at mean follow-up times of 6 to 33 months is 0% to 6.6%. 46 Although the studies with DES appear to have better outcomes, the major limitation to making reliable conclusions based on this data is that the efficiency of DES in certain complex situations is not clearly defined. These situations that are not clearly defined include cases in which there are totally occluded coronary vessels, diffuse disease or extensive lesions that requiring multiple stents, ostial lesions, and calcified vessels. In addition, situations that pose a high risk for DES restenosis are cases involving long stents, bifurcation stenting, small-vessel stenting, renal failure, and diabetes mellitus. The clinical utility of HCR in cases such as these may be limited. As mentioned, diabetic patients fall into a high-risk category for DES restenosis. Hence, these limitations would have to be taken into account when hybrid revascularization is considered in this particular subset of patients. Previous randomized controlled trials have shown CABG to be superior to PCI for the revascularization of diabetic patients. 47 The Future Revascularization Evaluation in Patients With Diabetes Mellitus: Optimal Management of Multivessel Disease (FREEDOM) trial is an international, multicenter, open-label, prospective, randomized superiority trial of PCI (specifically with DES) compared with CABG in diabetic patients with multivessel coronary artery disease. We predict that the FREEDOM trial is likely to show the same results as past trials, namely that CABG is superior to PCI in patients with diabetes mellitus, therefore implying that CABG also would be superior to HCR in diabetics.
In addition, it is important to put the results of the SYNTAX trial into perspective. The results of the SYNTAX trial 48 confirm that at 3 years CABG remains the treatment of choice for most patients with 3-vessel and left main disease, especially those patients with advanced coronary artery disease. Hence, the question arises as to why there would be such a difference in outcomes if DES were superior to SVG. Although the proven utility and superiority of the LIMA-to-LAD graft could certainly prove to be a contributing factor, the complexity involved with multivessel stenting is a very important point that has to be taken into consideration. It is also important to acknowledge that this trial is limited with regard to this topic because outcomes are only out to 3 years. Hence, only early graft failure is showing up, whereas late DES and SVG failure rates are not known at this point.
Antiplatelet Regimen and Limitations
The major limitation of the use of antiplatelet strategy during single-stage HCR is that no standardized guidelines currently exist. Although the goal is to prevent stent thrombosis while minimizing the risk of bleeding complications, the comparative data are limited. Different institutions have reported their experiences with various types of regimens. Kon et al 32 published their results on 15 patients who underwent minimally invasive direct coronary artery bypass immediately followed by PCI. Heparin reversal was not performed postoperatively, and the patients were loaded with 300 mg clopidogrel on arrival at the intensive care unit followed by 75 mg daily. Although no bleeding complications or acute stent thrombosis was reported, there was 1 reported case of stent failure (6.6%) at the 1-year follow-up. Bonatti et al 40 published their results on 5 patients who underwent totally endoscopic coronary artery bypass immediately followed by PCI. In their series, 300 mg clopidogrel and 100 mg aspirin were administered 12 hours preoperatively, and 75 mg clopidogrel was given daily for at least 6 months postoperatively. No bleeding complications were reported, and no stent restenosis or thrombosis was observed at the 6-month followup. Gilard et al 31 published their results on 70 patients in whom PCI was followed by minimally invasive direct coronary artery bypass within 16 hours. In these patients, 250 mg ticlopidine was administered after PCI, and 500 mg more was given postoperatively followed by 75 mg clopidogrel daily for 1 month. Their rationale for using ticlopidine was that is has a delayed onset of platelet action, so bleeding complications may be reduced during surgery. One patient was reported to have a bleeding episode after being placed on clopidogrel and treated via platelet transfusion with subsequent clopidogrel discontinuation. However, this caused subacute stent thrombosis, requiring a repeat PCI on day 7. Another patient was reported to have developed subacute stent thrombosis 6 days after PCI as a result of failure to take ticlopidine. No other bleeding complications were reported, and no other cardiac events were reported during a mean 33-month follow-up period. We published our results on 112 patients 42 who underwent CABG with concomitant PCI. For electively planned hybrid procedures, we administered a 300-mg loading dose of clopidogrel in the holding area. For unplanned hybrid procedures, when the decision to perform PCI was made during surgery, clopidogrel was given via nasogastric tube at the time the decision was made. We opted to use a 300-mg loading dose of clopidogrel rather than a 600-mg loading dose to attempt to balance the risks of bleeding complications against the risks of stent thrombosis. In our series, 3 patients (3%) required reoperation for bleeding and 1 patient (1%) developed in-stent thrombosis during their in-hospital course.
Hence, it is apparent that the antiplatelet strategy varies substantially among institutions performing HCR. The major limitation with antiplatelet strategy is that standardized guidelines have not been established and used.
Conclusions
The concept of HCR has clearly accrued significant popularity since its introduction more than a decade ago. Despite the fact that reports on the results of HCR from individual institutions have indicated satisfactory results, the clinical utility of HCR cannot be accurately assessed because there currently are no randomized controlled trials with long-term follow-up.
In addition to the technical and logistical limitations discussed previously, the indications for and selection of patients in whom HCR can be used as a treatment strategy are not yet defined. Although the National Heart, Lung, and Blood Institute recently initiated the first observational study to define the population eligible for HCR, the extent of its clinical utility is not defined or proven. Hence, despite some of its apparent advantages, the utility of HCR remains limited, which may hinder its progress to becoming the wave of the future.
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